growth of antigen-loss variants in certain mice that were initially protected against tumor formation (7) . After cloning in vitro, these tumor cells were no longer iysed by the CTL clones or by mixed leukocyte-tumor cell populations (MLTC). After several months of culture in vitro, two of five of these antigen-loss variants reverted to the original CTL-susceptible phenotype. Both the CTL-nonsusceptible and -susceptible variants were characterized on the molecular level. (b) We obtained long-lasting protection against tumor formation induced by M-MSV-M-MLV injection in syngeneic mice after intravenous injection of the same virusspecific CTL clones.
Materials and Methods
Mice. C57BL/6 (H-2b), DBA/2 (H-2d), and BALB/c (H-2 d) female mice were obtained from the animal colony of the Swiss Institute for Experimental Cancer Research. The breeding pairs for this colony originated from The Jackson Laboratory, Bar Harbor, ME.
Cells and Viruses. MBL-2 (H-2 b) and a subclone MBL-2.9, and LSTRA (H-2d), all M-MLV-induced lymphomas, were maintained by passage as ascites in C57BL/6 and BALB/c mice, respectively (15) . They were labeled with SlCr and used as target cells in 5~Cr release assays as described (15) , with one lytic unit (LU) equal to that number of effector cells required to give 50% lysis of 10 ~ labeled target cells in 3.5 h at 37°C (16) . L cells, A-9 cells, (an M-MLV-infected NIH-3T3 cell line), and Ab-X-MLV-infected NIH-3T3 cells (17) were grown in Duibecco's modified Eagle's medium supplemented with 10% fetal calf serum and antibiotics. Murine embryo fibroblasts (MEF) were prepared from 15-d-old C57BL/6 embryos and used as a second or third passage. Infection of cells was performed in the presence of 4 ~g]ml polybrene. B cell lymphoblasts were prepared (18) and infected with virus as described previously (19) .
Cell Labeling and Immunoprecipitations. Cells were labeled with [sSS]methionine (100 #Ci/ml) for 1 h, washed with phosphate-buffered saline (PBS), and iysed in a buffer containing PBS, 1% Triton X-100, 0.5% deoxycholate, and 0.1% sodium dodecyl sulphate according to Van Zaane et ai. (20) . Viral proteins were immunoprecipitated from cleared lysates by incubation of portions of the lysates (500,000 cpm) first with antisera directed against Rauscher MLV p30 or gp70 (obtained from the National Cancer Institute) and second with protein A-Sepharose, as described (21) . Immunoprecipitates were analyzed by electrophoresis on 10% SDS-polyacrylamide gels and radioactivity was visualized by exposure of EN~HANCE-treated gels to Kodak XAR-5 film.
Generation of M-MSV-M-MLV-specific CTL Clones. M-MSV-M-MLV-specific CTL clones were derived from C57BL/6 regressor mice by micromanipulation techniques as described (22, 7) . Lyt-2 ÷ CTL clones that demonstrated vigorous growth and strong specific cytolytic activity when tested on MBL-2.9 target cells were selected for in vivo protection studies (7) . MLTC cultures, which served as a source of an M-MSV-M-MLVspecific CTL population, were set up as reported previously (15) . C57BL/6 anti-DBA/2 CTL clones were derived by micromanipulation of immune peritoneal exudate lymphocytes obtained from primed C57BL/6 mice as described (7) .
In Vivo Protection Studies. The potential for M-MSV-M-MLV-specific CTL clones to protect mice against M-MSV-M-MLV-induced tumors was studied in two ways: (a) 4-wkold normal or irradiated (650 rad) C57BL/6 female mice were injected in the rear right footpad with 40 ttl of a stock preparation of M-MSV-M-MLV (7) . At the same time, various numbers of an M-MSV-M-MLV-specific CTL clone were injected intravenously and the mice monitored for tumor growth by measurement of footpad thickness using a 6 131 Vernier caliper (Etalon, Rolle, Switzerland). (b) In a second approach, 2 × 10 I-uridine (lSq-UdR)-labeled MBL-2.9 tumor cells were injected intraperitoneaily with the simultaneous intravenous injection of 20 X 106 M-MSV-M-MLV-specific CTL clone cells. Tumor cell destruction was monitored by whole-body counting techniques (23) . In additional experiments designed to investigate long-term survival in this tumor model, varying numbers of nonlabeled MBL-2.9 tumor cells were injected intraperitoneally, followed by 20 × 10 6 cells of an active CTL clone intravenously.
Isolation of Antigen-Loss Tumor Cell Variants. In the long-term protection studies described above, some mice developed ascites 30-60 d after tumor cell and CTL clone injection. Ascites cells were harvested from such mice, washed, and cloned by micromanipulation into single flat-bottom microwells without added filler cells. Those tumor cell lines which grew out after cloning (HEMO-4, 10s-2, and 10s-5 derived from MBL-2; and 1/7.1 and 1/7.2 derived from MBL-2.9) were then tested for the ability to serve as target cells for M-MSV-M-MLV-specific CTL populations. In certain cases, the antigen-loss tumor cell clones derived in vitro were readapted to growth as ascites and retested in the I-UdR whole-body counting assay system. DNA and RNA Analysis. Cellular DNA was isolated and analyzed by Southern hybridizations as described (24) . Restriction enzymes (Boehringer Mannheim) were used as described by the manufacturer. The DNA probes used in hybridizations were prepared as follows: DNA of plasmids MS-2 and MS-3 (24) was digested with Pst I; the inserts were isolated and self-ligated, yielding concatamers of up to eight times the insert's size. These products were nick-translated with [s~p]dATP (3,000 Ci/mmol) to specific activities of 7 × 108 cpm/t~g. Cytoplasmic RNA was isolated as described (25) . M-MLV-specific RNA was detected in Northern hybridizations using the MS-2 probe (25) .
Results

Target Molecule Recognized by M-MSV-M-MLV-specific CTL Clones. The mol-
ecule recognized by the Lyt-2 ÷ CTL clone CHM-14 that is specific for antigens induced by the oncogenic virus complex, M-MSV-M-MLV (7), is expressed on the surface of virus-infected but not uninfected cells. To characterize target molecules, we used the Ab-X-MLV mutant virus, which was derived from M-MLV by molecular recombination (17) . As shown in Fig. 1 , M-MLV harbors three genes, of which the first one, gag, codes for the precursor proteins gPr80 g~g and Pr65 (26) . gPr80 g~g is processed to gag membrane proteins gP85 gag and gP95 gag, while Pr65 is processed to p15, p12, p30, and pl0, which are found in the virion core. The Ab-X-MLV mutant, which harbors a point mutation in the gag gene, can no longer produce gPr80 g~g but is able to synthesize all other M-MLV-encoded proteins (17) . C57BL/6 "B lymphoblasts" and C57BL/6 murine embryo fibroblasts (MEF) were mock-infected or infected with either M-MLV or Ab-X-MLV. Cell cultures were examined for the synthesis of virusrelated proteins and for susceptibility to lysis by CTL clones. As shown in 2, MEF did not synthesize proteins recognized by anti-gp70 or anti-p30 antisera (A, lane a and B, lane e). In M-MLV-infected MEF, gPr80 gag, Pr65, and p30 were detected using anti-p30 antiserum (Fig. 2B, lane d) . In contrast, Ab-X-MLV-infected MEF synthesized Pr65 and low amounts o f p30 (Fig. 2 , B l a n e f and C lane h) but no gPr80 g~g. As shown in Table I , the M -M S V -M -M L Vspecific C T L clones efficiently lysed M-MLV-infected B lymphoblasts or MEF, but not mock-infected or Ab-X-MLV-infected cells. T h e observed difference in sensitivity to lysis of B lymphoblasts vs. MEF by C T L is most likely due to differences in inherent susceptibility to lysis (16) . Ab-X-MLV-and M-MLVinfected MEF showed indistinguishable patterns of synthesis of the e n v g e n eencoded proteins gp70 and pl 5 (E) ( Fig. 2A, lanes c and b) . T h e r e f o r e , although we cannot rule out an undetected role of gp70 in the recognition of the target cells by C T L , it is unlikely that gp70 or p15 (E) themselves serve as target molecules. Thus, these results suggest that the C T L clones specifically recognized "B lymphoblasts" and murine embryo fibroblasts were prepared and infected with virus as described in Materials and Methods. * Effector-to-target cell ratio, 4 h incubation. * Clone CHM-14 gave 155 LU/106 tested on MBL-2.9 target cells. 0 Clone CHM-14 gave 103 LU/106 tested on MBL-2.9 target cells.
the gag-related membrane protein gP85 gag, encoded by M-MLV, of which gPr80 gag is the precursor protein.
Isolation of Antigen-Loss Tumor Cell Variants after lmmunotherapy With a CTL Clone.
A modest protection against tumor formation was observed in our previous studies (7), in which 2 x 106 M-MLV-induced MBL-2.9 tumor cells were injected intraperitoneally, followed by intravenous injection of 20 × 106 CTL clone CHM-14. When lower numbers of MBL-2.9 cells were injected, a much more significant long-term survival of mice was observed (up to 150 d after injection). However, after 1-2 mo, certain mice that had been initially protected developed ascites. Tumor cells of such mice were cloned in vitro, labeled with 5~Cr, and tested for their ability to serve as target cells for virusspecific CTL clones. As shown in Table II , several of the antigen-loss variant tumor cell clones were no longer lysed by either the virus-specific CTL clones or an M-MSV-M-MLV-specific MLTC population. We determined that these antigen-loss variants expressed unaltered levels of H-2 b surface alloantigens, as tested using monoclonal antibodies and cell sorter analysis (data not shown). Furthermore, we show that they are lysed by allogeneic BALB/c anti-C57BL/6 MLC cells containing CTL directed against C57BL/6 H-2 b alloantigens (Table  II) .
Transcriptionally Silent M-MLV Genomes in Antigen-Loss Variants. Several of the CTL-resistant antigen-loss tumor cell variants were examined for expression of M-MLV gag-related proteins. All of the variants were negative for M-MLV protein expression compared with the parental tumor cell line (data not shown). This phenotypic change could be due to loss of M-MLV genomes or to absence of expression of M-MLV DNA. Three independent antigen-loss variants, 1/7.1, 1/7.2, and HEMO-4, were examined in detail with the M-MLV-specific DNA 
o g e n o u s MLV, using MS2 as probe, D N A o f the t h r e e variants a n d o f MBL-2.9 was digested with K p n I, which g e n e r a t e d a 1.3 kilobasepair (kbp) f r a g m e n t r e c o g n i z e d with MS-2, which is diagnostic for M -M L V (24) . T h e e n d o g e n o u s M L V D N A give rise to f r a g m e n t s o f 1.5 a n d 1.8 kb u p o n digestion with Kpn I, r e c o g n i z e d with MS-2 (27) . As shown in Fig. 3, b-d , all t h r e e variants retained M -M L V g e n o m e s , as indicated by the presence o f the 1.3 kbp Kpn I f r a g m e n t , which was also detected in Kpn I-digested MBL-2.9 DNA (Fig. 3a) . In contrast, M-MLV-negative mouse cells (L cells) only harbor the 1.5 and 1.8 kbp fragments (Fig. 3e) . Using MS-3 as a probe, we observed the 2.9 kbp Kpn I M-MLV fragment in the antigen-loss variants (not shown). However, the size analysis of RNA synthesized in MBL-2.9 cells (Fig. 4a) and in the antigen-loss variants (Fig. 4, b-d Reversion iof Antigen-Loss Variants to CTL-susceptible Phenotype. Upon prolonged culture in vitro (3 mo), two of the five cloned antigen-loss tumor cell variants reverted back to their original phenotype, i.e., they were again lysed by the virus-specific CTL clone CHM-14 when tested in a 5~Cr release assay, suggesting the reexpression of M-MLV genomes in these cells. One of these CTL-susceptible revertants (1/7.2, tested on February 16, 1984, hereafter referred to as 1/7.2R) (Fig. 5 ) was analyzed at the molecular level. A preliminary DNA analysis had revealed that the 1/7.2R cells harbored an amplified number of M-MLV genomes, which might be responsible for the expression of M-MLV genomes. To quantitate this result and to examine the state of methylation of the M-MLV genomes, we performed experiments comparing 1/7.2R and MBL-2.9 cells as well as L cells, which do not harbor M-MLV genomes. For the methylation studies we used selective inhibition of the restriction enzyme Hpa II by methylation of the second cytosine in the recognition sequence CCGG. The isoschizomer Msp I cleaves this sequence regardless of the state of methylation (28) . DNA of the three cell lines was digested with Kpn I, Kpn I/Hpa II or Kpn I/Msp I and analyzed using the MS-2 probe (Fig. 3) . As expected, the 1.3 kbp Kpn I M-MLV fragment detected in 1/7.2R (Fig. 3h) and MBL-2.9 cells (k) is absent from L cells (e). Densitometric scanning of lanes h and k revealed that 1/7.2R yielded approximately eight times more of the 1.3 kbp fragment than did MBL-2.9, in contrast to 1/7.2 cells, which contained as many M-MLV genomes as did MBL-2.9 cells (Fig. 3, a and c) . Digestion of 1/7.2R and MBL-2.9 DNA with Kpn I/Msp I produced a 0.7 kbp fragment detectable with MS-2, which was amplified eight times in 1/7.2R cells (Fig. 3, i and 1) , whereas no such fragment was found in L cell DNA (f). Digestion with Kpn I/Hpa II yielded 0.7 kbp fragments in 1/7.2R and MBL-2.9 DNA (Fig. 3,j and m) , but not in L cell DNA (g), indicating the presence of nonmethylated M-MLV genomes in 1/7.2R and MBL-2.9 cells. Upon digestion of 1/7.2R DNA with Kpn I/Hpa II, we also observed the 1.3 kbp Kpn I fragment (Fig. 3j) , indicating the presence of some methylated M-MLV genomes in these cells. Consistent with the detection of an amplified number of nonmethylated M-MLV copies in 1/7.2R cells, we observed the expression of the 8.2 and 3.2 kb M-MLV-related RNA species in these cells ( Fig. 4g ), but not in the antigen-loss variants 1/7.1 and HEMO-4 (Fig. 4,fand   h ).
Expression of an Aberrant gag Precursor Protein in 1/7.2R Cells.
The susceptibility of the 1/7.2R cells to lysis by CTL clone CHM-14 as well as the expression of M-MLV-specific mRNA suggested that these tumor cells reexpressed gagrelated membrane proteins. The precursor of these proteins was characterized by metabolic labeling of 1/7.2R cells and immunoprecipitation with anti-p30 antiserum (Fig. 2, panel C) . M-MLV-and Ab-X-MLV-infected MEF were included as controls: these cells synthesized, respectively, gPr80 g~g, Pr65 and p30 (Fig. 2C, lane g ) and Pr65 and p30 (lane h). In 1/7.2R cells, Pr65 and p30 as well as large amounts of a new gag-related protein, Pr92, were detected ( Fig.  2 C, lane i) ; surprisingly, no gPr80 gag was observed in these ceils. Also, whereas Ab-X-MLV-infected MEF only synthesized the lower molecular weight species of the P r l 8 0 gagp°l doublet, which is related to Pr65 (Fig. 2C, lane h) , M-MLVinfected MEF and 1/7.2R cells expressed both species of P r l 8 0 gagp°l (12) (lanes  g and i) . Apparently, the M-MLV genomes that are expressed in 1/7.2R cells have undergone a mutational event in vitro, leading to the disappearance of gPr80 g~g and its replacement by Pr92, but leaving the synthesis of Pr65 unaffected.
gag Region Recombination in 1/7.2R M-MLV Genomes. We attempted to determine the region of the 1/7.2R M-MLV genomes in which the mutation occurred by DNA analysis using MS-3 as a probe. MS-3 is specific for the N-terminal region of the M-MLV gag gene (Fig. 1) (24) . In preliminary experiments using MS-3 to detect the 2.9 kbp Kpn I M-MLV fragment, we unexpectedly observed the presence of an additional fragment of 3.2 kbp in 1/7.2R DNA, suggesting the insertion of 300 bp of DNA in the 2.9 kbp Kpn I region of some M-MLV genomes in 1/7.2R cells. A restriction enzyme analysis was carried out to identify the site of insertion (Fig. 6) . Digestion of 1/7.2R DNA with Kpn I/Sac I, Kpn I/ Pvu II, or Pvu II/Pst I generated fragments that were detected with MS-3 of 2.6 and 2.9 kbp (Fig. 6a ), 1.5 and 1.8 kbp (b), and 0.65 kbp (c), respectively. Digestion of L cell DNA with the same combinations of enzymes did not yield fragments detectable with MS-3 (Fig. 6, d-f ). Consistent with previous data (24), digestion of MBL-2.9 DNA with Kpn I/Sac I, Kpn I/Pvu II, or Pvu II/Pst I generated fragments of, respectively, 2.6, 1.5, and 0.65 kbp (not shown). Based on the M-MLV restriction map and the location of the MS-3 probe (see Fig. 1 ), we conclude that the 300 bp insertion event occurred in the gag region between the Kpn I site in the 5' L T R and the two Pst I sites. Nucleotide sequence analysis of this fragment of M-MLV DNA has shown (26) that the N-termini of gPr80 g~g and Pr65 are located in this region, although the precise initiation site of the Restricted DNA were analyzed as described in Fig. 3 , using a nick-translated, M-MLV-specific MS-3 probe (24) and the same marker DNA. gPr80 gag N-terminus remains to be determined. The size difference between Pr92 and gPr80 gag can be accounted for by translation of the 300 bp DNA insert during the synthesis of gag-related proteins in 1/7.2R cells. Since the size of Pr65 was not altered in 1/7.2R cells, we conclude that the insertion event took place in a region of the M-MLV genome that codes exclusively for the gag membrane precursor protein.
Inhibition of Virus-induced Tumor Formation by the Intravenous Injection of Virusspec~c CTL Clones.
To study the potential protective effects in vivo of the CTL clones that specifically recognize gag-related membrane proteins on M-MLVinfected target cells, mice were injected simultaneously with M-MSV-M-MLV in the footpad and injected intravenously with 20 × 10 6 of either virus-specific cloned CTL, syngeneic irradiated spleen cells, or anti-H-2d-specific cloned CTL (Fig. 7 ). Mice injected with virus and with spleen cells developed tumors in the footpad and died. In contrast, the intravenous injection of virus-specific CTL clones CHM-14, MOM-I.1, or MOM-2.1 resulted in a complete, long-lived protection against tumor induction in C57BL/6 mice that had been sublethally irradiated (650 rad) 16 h before injection (Fig. 7, A and B) . The injection of another group of mice with 20 × 10 6 CTL clone CHA-11, specific for H-2 d alloantigens, had no inhibitory effect on tumor induction (Fig. 7, A and B) . This CTL clone has been shown (7) to be active in a specific manner against H-2 d tumor targets in vivo. Thus, the prevention of tumor formation was specific with respect to the CTL clone injected. In additional experiments, we have shown that injection of the virus-specific CTL clone CHM-14 has no effect on the growth of H-2 d allogeneic tumors in the peritoneal cavities of sublethally irradiated mice, which were protected at the same time against M-MSV-M-MLVinduced tumor formation in the footpad (data not shown). In this report we describe the protection of mice against virus-induced tumors by treatment with virus-specific CTL clones. These same CTL clones had been shown previously to induce the destruction of M-MLV-induced lymphoma cells after intravenous injection (7) . Similar experiments in other systems have used either mixed populations of CTL (8, 29) or cloned CTL (3, 30) . The availability of cloned CTL and specific antisera against M-MLV and Ab-X-MLV gag and env polypeptides has allowed us to characterize the M-MLV-encoded protein gP85 gag as a target molecule recognized by the cloned CTL. Ab-X-MLV-infected cells deficient in the synthesis of gP85 gag were not lysed by the virus-specific CTL clones. The amounts of gp70 and p15 (E) synthesized in Ab-X-MLV-and M-MLV-infected target cells were shown to be indistinguishable; therefore, we believe it unlikely that the env-related proteins act as target molecules for the virus-specific CTL clones used in this study. Several reports have suggested the existence of CTL populations specific for gag gene products (31) (32) (33) . Plata et al. (33) investigated the inhibition of CTL activity by anti-p30 monoclonal antibodies that recognized p30 determinants on Friend-, Rauscher-, Moloney-, and Gross-MLV-infected cells. However, the authors detected inhibition of cytolysis only of Gross-MLV-infected cells using a mixed population of Gross-MLV-specific CTL. Other reports (34, 35) have suggested that the viral env gene products gp70 and p15 (E) could be target molecules recognized by CTL, but experiments designed to detect blocking of CTL activity by gp70 or anti-gp70 antibodies have yielded contradictory results (9, 13, 14) . Flyer et al. (10) demonstrated the existence of gp70-or p15 (E)-specific CTL using a mixed population of CTL and target cells transfected with and expressing only the M-MLV env gene. Therefore, our data suggest that both gag and env gene products can act as target molecules for virus-specific CTL, depending on the system under investigation, gP85 gag, identified in this report as a target molecule for M-MSV-M-MLV-specific CTL lysis, was previously (36, 37) shown to be identical to the Gross cell surface antigen (GCSA), which is expressed on cells infected by viruses of the FMR group and by Gross-MLV. Green (32) showed a correlation between GCSA expression and susceptibility of Akv-induced tumor cells to CTL lysis.
The two primary gag gene products, gPr80 gag and Pr65, are synthesized independently, gPr80 gag contains all Pr65 peptides as well as 4-6 kilodaltons of unique amino-terminal peptides (11, 12). Several viruses, derived from or highly related to M-MLV, do not synthesize proteins related to M-MLV gPr80 gag (38, 39) . Since M-MLV only codes for Pr65 (40) , the target molecule recognized by the virus-specific CTL clones must be encoded exclusively by the M-MLV genome. This suggests that the observed protection of mice against M-MSV-M-MLV-induced tumor formation by the virus-specific cloned CTL was due to selective destruction of cells infected with the virus complex, although we cannot exclude the influence of other factors (41) leading to the elimination of virusinfected cells.
A Possible Role for CTL in MLV-induced Leukemogenesis. The identification of gP85 gag as a target molecule recognized by virus-specific CTL suggests a possible involvement of such CTL in the development of leukemias induced by nonleu-kemogenic MLV. Their specific cytolytic activity may play a role during the selection of cells infected with recombinant leukemogenic MLV, such as mink cell focus-inducing viruses (MCF) (42) , during the preleukemic stage. Analysis of the structure of MCF viruses shows that they arose from multiple recombination events between ecotropic and xenotropic MLV (24, 43) . Based on previous studies and the present data, the following model could account for their selection: an endogenous nonleukemogenic MLV can be expressed after birth in certain strains of mice (for instance Akv) (43) or, when it is injected into newborn mice, it can infect several organs. The MLV can recombine either with the LTR region of a xenotropic MLV (44, 45) or with the coding region of other xenotropic MLV. In the latter situation (46, 47) , the viraily encoded xenotropic cell membrane proteins, such as gPr85 g~g or gp70, will not be recognized by specific CTL induced as a result of the original MLV infection, leading to appearance of nonleukemogenic class II MCF viruses. In the situation where the original MLV recombines only with specific xenotropic Us LTR sequences, the resulting viruses generally will also be nonleukemogenic. Cells infected with such MLV will be eliminated by specific CTL, unless these MLV recombine further with xenotropic MLV in their gag, pol, and/or env regions. Viruses resulting from these secondary recombination events in the env and possibly also the gag region possesses the structure of leukemogenic class I MCF viruses (24, 44) . Of course, additional factors (e.g., antibody formation) most likely play an important role in these and other steps of MLV-induced leukemogenesis. In addition, Chesebro et al. (48) showed that in some mouse strains and cell types, the expression of MCF viruses may not be required in ieukemogenesis. The actual mechanism of transformation of virus-infected target cells is not known. The MCF viral env gene product itself has been suggested to play a role in the transformation process (49, 50) . It could also stimulate the continuous recruitment of T cells, thereby enhancing the probability of spontaneous transformation (51) . Alternatively, the insertion of MLV in the vicinity of oncogenes may lead to the activation of such genes, resulting in the transformation of cells (52, 53) . Some aspects of the model presented above can be tested: Are MCF-type viruses generated during MLV-induced leukemogenesis in mice that are unable to generate virus-specific CTL (41)? Do viruses deficient in the synthesis of gag membrane proteins induce leukemias in C57BL/6 mice and, if so, what MCFtype viruses, if any, can be isolated from leukemic tissues?
Recombination of MLV Genomes In Vitro. The antigen-loss variants were detected because the variants grew as ascites, while the parental tumor cells were eliminated by virus-specific CTL. Emergence of antigen-loss variants has been demonstrated both in vivo (54) and in vitro (55) , but the mechanism for their generation remains to be determined. From methylation experiments we concluded that, in the revertant cell line 1/7.2R, the transcriptionally silent character of the original M-MLV genomes may be due to methylation of these viral genomes in vivo. Methylation events have been described both in vivo (28) and in tissue culture (56) that lead to the loss of expression of the genes under investigation. In the latter study (56) the appearance of flat revertants of Fujinami sarcoma virus (FSV)-transformed cells was shown to be due to hypermethylation of the FSV genome in vitro. The authors observed the reappearance of trans-formants, again harboring the FSV genome in a nonmethylated state. These retransformants resembled (56) the revertant antigen-loss variant 1/7.2R, which reexpressed a gag membrane protein. However, in addition to the nonmethylated state of some M-MLV copies in 1/7.2R cells, the insertion of 300 bp DNA of unknown origin into the gag region of these M-MLV genomes was detected. The RNA transcribed from M-MLV genomes harboring this inserted DNA is translated, leading to the addition of ~100 amino acid residues to the gPr80 g~g protein. Indeed, a Pr92 protein was detected in 1/7.2R cells. Many cases of gag region recombinations in vivo have been described (57, 58) , but were rarely observed in tissue culture (59) . The gag recombination event resulting in the expression of Pr92 in 1/7.2R cells most likely occurred in only one or a few ceils of the antigen-loss variant 1/7.2R. Recently (Van der Hoorn, unpublished results), we transmitted virus shed by 1/7.2R cells to C3H10T1/2 murine fibroblasts and showed the expression of Pr92 in these cells. Therefore, we believe that this virus, which probably originated in a restricted number of the 1/7.2 R cells, spread through the culture. This would explain the CTL-susceptible phenotype of the 1/7.2R cells. A comparison of our data with the M-MLV DNA sequence shows that the insertion event occurred in the region between nucleotides 32 and 621 (26) 
